TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study
While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.
You may also be interested in...
Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.
The firm has revealed its anti-tau candidate showed promise in a late-stage Alzheimer’s study several years after a disappointing failure, but data are yet to be announced in full.
Hopes that the Phase II TAURIEL trial could potentially validate the anti-tau antibody approach to treating Alzheimer's have been dashed as semorinemab did not meet its endpoints.